ActoKine Therapeutics is focused on advancing drug development through innovative research in cytokines and biologics. The company has two primary product candidates: AK-1, which serves as an adjunct to cancer therapy, and AK-2, an anti-viral drug. AK-1 is a patented cytokine that has shown promise in protecting normal cells from radiation and chemotherapy-induced damage while simultaneously sensitizing tumor cells to these treatments. This dual action allows AK-1 to mitigate the toxic side effects of chemotherapy, such as hair loss, while enhancing the efficacy of cancer therapies against tumor cells. The company aims to explore new drug indications and rescue strategies for existing drugs that have previously failed in clinical trials.

In addition to AK-1, ActoKine has developed AK-2, which offers protection to normal cells against viral infections while selectively targeting and killing virus-infected cells. The research at ActoKine emphasizes the discovery of novel biologics and the exploration of new functions for known biologics across various diseases, thereby creating opportunities in niche markets. The company's approach includes identifying target genes induced by AK-1 in normal cells, which can be leveraged for screening small molecule drugs that could replace AK-1 in protecting normal cells from the toxic effects of cancer therapies.

United States

Discovering novel functions of existing molecules

Chestnut Hill, Massachusetts, United States

Actokine

Company Details